5 news items
Why NKGen Biotech Stock Is Moving Higher Monday
NKGN
20 May 24
to be well-tolerated with no reported drug-related adverse events.”
The Phase 2 study will assess efficacy and further safety of SNK01
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
compared to only four total doses in the initial proof-of-concept study. Three patients were enrolled in the Phase I portion to assess the safety
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGN
25 Apr 24
, and 4 x 109 cells) in patients with either mild, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and extensive CSF
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data In Alzheimer's Disease At The Tau2024 Global Conference
NKGN
25 Mar 24
, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
NKGN
25 Mar 24
with either mild, moderate, or severe AD (Median MMSE of 14). Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed
- Prev
- 1
- Next